EXTH-48. GALECTIN-1 INHIBITION SENSITIZES RADIATION TREATMENT IN A PRE-CLINICAL MODEL OF GLIOBLASTOMA

Radioresistance remains a major clinical challenge in glioblastoma (GB) therapy. However, the mechanism for the development of radioresistance in GB is unclear. Mounting evidence suggests that Galectin-1 (Gal1: a carbohydrate-binding protein galectin-1) contributes to the radioresistance of GB tumor...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Neuro Oncol
Glavni autori: Henderson, Fraser, Das, Arabinda, Kanginakudru, Indira, McDonald, Daniel G, Kosnik Infinger, Libby, Vandergrift III, William, Varma, Abhay, Vanek, Kenneth N, Lindhorst, Scott, Patel, Sunil, Cachia, David
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2019
Teme:
Experimental Therapeutics
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847700/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.380
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items